Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...

The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of the body, shipped to a specialized facility, genetically reprogrammed, ...

In this study, researchers aimed to determine whether BCMA-directed CAR T-cell therapy is a feasible first-line option for newly diagnosed multiple myeloma patients who are ineligible for ASCT.

Researchers were perplexed when the Food and Drug Administration announced it was investigating whether CAR-T therapy, one of the most effective treatments for blood cancers, could cause lymphoma.

Remove this text and use the embed button to add an image. Although still in early clinical trials, if successful, E-SYNC could one day become the first CAR-T therapy to treat the aggressive brain ...

The United States Food and Drug Administration issued a new warning linking increased cancer risk to CAR-T cancer therapy, a treatment pioneered at Penn. Chimeric antigen receptor (CAR) T cell ...

U.S. FDA Grants to Wugen’s WU-CART-007 Breakthrough Therapy Designation for Treatment of Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia / T Cell Lymphoblastic Lymphoma -- Breakthrough ...

Since the FDA approved the first CAR-T therapy back in August 2017, high prices, small patients pools and limited manufacturing capacity have at times hindered these cell-based treatments. As ...